Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1

Leukemia

Volumn 26, Issue 7, 2012, Pages 1555-1563

  Soliera, A R ^a,b   Mariani, S A ^a   Audia, A ^a   Lidonnici, M R ^a   Addya, S ^a   Ferrari Amorotti, G ^b   Cattelani, S ^b   Manzotti, G ^b   Fragliasso, V ^b   Peterson, L ^c   Perini, G ^d   Holyoake, T L ^e   Calabretta, B ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cell survival; oncogene; therapy; tumor suppressor gene

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; GFI1 PROTEIN; PROTEIN MCL 1; STAT5 PROTEIN; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84863777387     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.19     Document Type: Article

References (41)

1. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene 2007; 26: 6816-6828.
2. Laslo P, Spooner CJ, Warmflash A, Lancki DN, Lee HS, Sciammes R et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006; 126: 755-766.
3. Chou ST, Khandros E, Baley LC, Nichols KE, Vakoc CR, Yao Y et al. Graded expression of PU1/Sfp1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood 2009; 114: 983-994.
4. Sakamoto H, Dai G, Tsujino K, Huang X, Fujimoto T, Mucenski M et al. Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development. Blood 2006; 108: 896-903.
5. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPalpha. Immunity 2004; 21: 853-863.
6. Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 2007; 26: 6829-6837.
7. Radomska HS, Huettner CS, Zhang P, Chen T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
8. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003; 3: 89-101.
9. Nerlov C. C/EBPa mutations in acute myeloid leukemias. Nat Rev Cancer 2004; 4: 394-400.
10. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBPa expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
11. Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C/EBPa exression in BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651-52659.
12. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t (8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
13. Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Donato N et al. Leukemogenesis induced by wild-type and ST1571-resistant BCR/ABL is potently suppressed by C/EBPa. Blood 2006; 108: 1353-1362.
14. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPa is required for induction of granulocytic differentiation. Blood 2003; 102: 1267-1275.
15. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001; 8: 817-828.
16. Xu X, Lindberg B, Wewer UM, Friis-Hansen L, Nerlov C. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell 2001; 107: 247-258.
17. Müller C, Calkhoven CF, Sha X, Leutz A. The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest. J Biol Chem 2004; 279: 7353-7358.
18. D'Alo F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P et al. The amino terminal of E 2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood 2003; 102: 3163-3171.
19. Lidonnici MR, Audia A, Soliera AR, Prisco M, Ferrari-Amorotti G, waldron et al. Expression of the transcription repressor Gfi-1 is regulated by C/EBP(alpha) and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Res 2010; 70: 7949-7959.
20. Hock H, Haniblen MJ, Rooke HM, Schindler JW, Saleque S, Fujiwara Y et al. Gfi-1 restricts proliferation and preserves functional integrity of hematopoietic stem cells. Nature 2004; 431: 1002-1007.
21. Zeng H, Yucel R, Kosan C, Klein-Hitpass L, Moroy T. Transcription factor Gfi-1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO J 2004; 23: 4116-4125.
22. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G et al. P53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37-48.
23. Dahl R, Iyer SR, Owens KS, Cuylear DD, Simon MC. The transcriptional repressor GFI-1 antagonizes PU 1 activity through protein-protein interaction. J Biol Chem 2007; 282: 6473-6483.
24. Hock H, Hamblen MJ, Rooke HM, Trover D, Bronson RT, Cameron S et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 2003; 18: 109-120.
25. Schuringa JJ, Chung KY, Morrone G, Moore MA. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 2004; 200: 623-635.
26. Wierenga ATJ, Vellenga E, Schuringa JJ. Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol 2008; 28: 6668-6680.
27. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-1104.
28. Campbell CJV, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010; 116: 1433-1442.
29. Onishi M, Nosaka T, Misawa ALF, Gorman DM, McMahon M, Miyajima A et al. Identification and characterization of a constitutively active STAT 5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18: 3871-3879.
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
31. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
32. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madirayan SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-19517.
33. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-07 (obatoclax). Cancer Res 2008; 68: 3413-3420.
34. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT 5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421-3429.
35. Kerenyi MA, Grebien F, Gehart H, Schirfer M, Artaker M, Kovacic B et al. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood 2008; 112: 3878-3888.
36. Aichberger KJ, Mayerhofer M, Ktauth M-T, Skvana H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
37. Horman SR, Velu SC, Chaubey A, Bourdeau T, Zhu J, Paul WE et al. Gfi-1 integrates progenitor versus granulocytic transcriptional programming. Blood 2009; 113: 5466-5475.
38. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcf/abl+ human leukemia cells in association with signal transducer and activation of transcription 5 innhibition and myeloid cell leukemia-1 downregulation. Mol Pharmacol 2007; 72: 788-795.
39. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnick JL et al. FLT3-ITD upregulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT 5 activation. Blood 2009; 114: 5024-5043.
40. Allan EK, Holyoake TL, Craig AR, Jorgensen HG. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011; 25: 985-994.
41. Cheng S, Gao N, Zhang Z, Chen G, Budhraja A, Ke Z et al. Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax. Clin Cancer Res 2010; 16: 5679-5691.